Dr. Lal PathLabs Limited (BOM:539524)
India
· Delayed Price · Currency is INR | Market Cap | 243.21B |
| Revenue (ttm) | 24.61B |
| Net Income (ttm) | 4.87B |
| Shares Out | n/a |
| EPS (ttm) | 58.40 |
| PE Ratio | 49.93 |
| Forward PE | 49.02 |
| Dividend | 24.00 (0.83%) |
| Ex-Dividend Date | Jun 6, 2025 |
| Volume | 1,343 |
| Average Volume | 3,701 |
| Open | 2,900.00 |
| Previous Close | 2,875.85 |
| Day's Range | 2,868.75 - 2,934.75 |
| 52-Week Range | 2,295.10 - 3,645.00 |
| Beta | n/a |
| RSI | 56.28 |
| Earnings Date | Jul 31, 2025 |
About Dr. Lal PathLabs
Dr. Lal PathLabs Limited operates laboratories for carrying out pathological investigations in India and internationally. The company provides pathological investigations of various branches of bio-chemistry, hematology, histopathology, microbiology, electrophoresis, immuno-chemistry, immunology, virology, cytology, and other pathological and radiological investigations. It also offers phlebotomist training programs. The company was founded in 1949 and is based in Gurugram, India. [Read more]
Financial Performance
In 2024, Dr. Lal PathLabs's revenue was 24.61 billion, an increase of 10.54% compared to the previous year's 22.27 billion. Earnings were 4.87 billion, an increase of 36.17%.
Financial StatementsNews
Dr. Lal PathLabs Q4 FY25: Revenue up 10.48% to 602.6 crore, Net profit surges 81% YoY
Dr. Lal PathLabs Ltd reported a strong financial performance for the fourth quarter ended March 31, 2025, with consolidated net profit rising 81% year-on-year to ₹155.5 crore, up from ₹85.8 crore in Q...
Dr Lal Path Labs stock jumps 3.46% after strong Q2 earnings and positive brokerage calls
Shares of Dr Lal Path Labs surged by 3.46%, rising ₹112.75 to trade at ₹3,368.45 on the NSE at 9:16 AM. The stock’s upward movement follows the release of strong Q2 FY25 earnings and positive brokerag...
Dr Lal Path Labs share price: Buy, Sell, or Hold? Check what brokerages are saying
Several brokerages have shared their views on Dr Lal Path Labs. Here’s what they are saying: Goldman Sachs: Goldman Sachs has maintained its sell call on Dr Lal Path and raised the share price target ...
UBS maintains buy call on Dr LalPath Labs, expects 7.7% upside in share price
UBS has maintained its buy rating on Dr LalPath Labs, with a share price target of ₹3,500, indicating a 7.7% upside from the current market price (CMP). The company’s Q2 performance was robust, showin...
Dr Lal PathLabs Q2 FY25: Revenue up 9.8% YoY to ₹660.2 crore, net profit rises 18.1% YoY to ₹130.8 crore
Dr Lal PathLabs has reported solid financial results for Q2 FY25, showing notable growth in both revenue and net profit on a year-on-year (YoY) basis. Key Financial Highlights: Revenue for Q2 FY25 sto...